JP2016540030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016540030A5 JP2016540030A5 JP2016540981A JP2016540981A JP2016540030A5 JP 2016540030 A5 JP2016540030 A5 JP 2016540030A5 JP 2016540981 A JP2016540981 A JP 2016540981A JP 2016540981 A JP2016540981 A JP 2016540981A JP 2016540030 A5 JP2016540030 A5 JP 2016540030A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- vortioxetine
- nalmefene
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 20
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims 10
- 229960005297 nalmefene Drugs 0.000 claims 10
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 claims 10
- 229960002263 vortioxetine Drugs 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201300710 | 2013-12-20 | ||
| DKPA201300710 | 2013-12-20 | ||
| DKPA201400590 | 2014-10-16 | ||
| DKPA201400590 | 2014-10-16 | ||
| PCT/EP2014/078515 WO2015091833A1 (en) | 2013-12-20 | 2014-12-18 | Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016540030A JP2016540030A (ja) | 2016-12-22 |
| JP2016540030A5 true JP2016540030A5 (enExample) | 2018-01-18 |
| JP6448645B2 JP6448645B2 (ja) | 2019-01-09 |
Family
ID=52146489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540981A Active JP6448645B2 (ja) | 2013-12-20 | 2014-12-18 | メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10376506B2 (enExample) |
| EP (1) | EP3082815B1 (enExample) |
| JP (1) | JP6448645B2 (enExample) |
| KR (1) | KR20160093025A (enExample) |
| CN (1) | CN105828821B (enExample) |
| AU (1) | AU2014368548B2 (enExample) |
| CA (1) | CA2933733A1 (enExample) |
| CL (1) | CL2016001570A1 (enExample) |
| ES (1) | ES2694352T3 (enExample) |
| IL (1) | IL246253A0 (enExample) |
| MX (1) | MX368870B (enExample) |
| RU (1) | RU2679661C1 (enExample) |
| SG (1) | SG11201604944PA (enExample) |
| WO (1) | WO2015091833A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018003930A2 (pt) * | 2016-07-01 | 2018-09-25 | H Lundbeck As | regimes de dosagem de vortioxetina para início rápido de efeito antidepressivo |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| JP7549576B2 (ja) | 2018-11-06 | 2024-09-11 | パーデュー、ファーマ、リミテッド、パートナーシップ | オピオイドアンタゴニストを送達するための組成物及び方法 |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
| TW202400135A (zh) | 2022-03-07 | 2024-01-01 | 美商健生醫藥公司 | 包含阿替卡普蘭之組成物 |
| TW202547487A (zh) * | 2024-03-18 | 2025-12-16 | 學校法人東京理科大學 | 失樂症的治療或預防用醫藥組成物 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013740A (en) | 1990-03-22 | 1991-05-07 | Hillel Glover | Method for treating emotional numbness and coma |
| US5028612A (en) | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
| US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
| US6528518B2 (en) * | 2000-12-21 | 2003-03-04 | The Mclean Hospital Corporation | Treatment of depression with kappa receptor antagonists |
| US20030087896A1 (en) | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
| PL368612A1 (en) * | 2001-08-14 | 2005-04-04 | Biotie Therapies Corporation | Method of treating alcoholism or alcohol abuse |
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| DK1485051T3 (da) * | 2002-03-20 | 2008-09-08 | Euro Celtique Sa | Fremgangsmåde til indgivelse af buprenorphin til behandling af depression |
| US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| US20070179168A1 (en) * | 2005-11-28 | 2007-08-02 | Orexigen Therapeutics, Inc. | Methods of treating anxiety disorders |
| CN101432011A (zh) * | 2006-02-27 | 2009-05-13 | 亚历山大·米哈洛 | 通过诱导逆适应调节神经递质系统的方法 |
| WO2008066916A1 (en) | 2006-11-30 | 2008-06-05 | The Mclean Hospital Corporation | Methods for the treatment of mood disorders |
| DE502007002185D1 (de) * | 2006-04-04 | 2010-01-14 | Emodys Gmbh | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen |
| US20070259939A1 (en) * | 2006-05-04 | 2007-11-08 | Accelerated Technologies | Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
| KR101627901B1 (ko) | 2006-06-16 | 2016-06-13 | 하. 룬트벡 아크티에 셀스카브 | 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진 |
| TW200848411A (en) | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
| TW200932225A (en) * | 2007-12-14 | 2009-08-01 | Lundbeck & Co As H | 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine |
| MY158251A (en) | 2009-05-25 | 2016-09-30 | H Lundbeck As | Method for the preparation of nalmefene hydrochloride |
| WO2011020030A2 (en) * | 2009-08-13 | 2011-02-17 | The General Hospital Corporation | Methods and compositions to prevent addiction |
| WO2011136376A1 (ja) | 2010-04-30 | 2011-11-03 | 武田薬品工業株式会社 | 腸溶性錠剤 |
| RS55777B1 (sr) | 2010-11-05 | 2017-07-31 | H Lundbeck As | Postupak za proizvodnju naltreksona |
| JP6406713B2 (ja) * | 2013-01-30 | 2018-10-17 | ファーモレックス セラピューティクス， インコーポレイテッド | 低用量薬剤によるうつ病および他の疾患の処置 |
| WO2014170351A1 (en) * | 2013-04-17 | 2014-10-23 | H. Lundbeck A/S | Nalmefene for treatment of patients with mood disorder |
| CA2909506C (en) | 2013-04-17 | 2021-04-20 | H. Lundbeck A/S | Nalmefene for treatment of patients with anxiety disorder |
-
2014
- 2014-12-18 MX MX2016007947A patent/MX368870B/es active IP Right Grant
- 2014-12-18 WO PCT/EP2014/078515 patent/WO2015091833A1/en not_active Ceased
- 2014-12-18 JP JP2016540981A patent/JP6448645B2/ja active Active
- 2014-12-18 ES ES14818973.1T patent/ES2694352T3/es active Active
- 2014-12-18 RU RU2016123972A patent/RU2679661C1/ru not_active IP Right Cessation
- 2014-12-18 SG SG11201604944PA patent/SG11201604944PA/en unknown
- 2014-12-18 CA CA2933733A patent/CA2933733A1/en not_active Abandoned
- 2014-12-18 AU AU2014368548A patent/AU2014368548B2/en not_active Ceased
- 2014-12-18 US US15/105,701 patent/US10376506B2/en active Active
- 2014-12-18 EP EP14818973.1A patent/EP3082815B1/en active Active
- 2014-12-18 CN CN201480069586.5A patent/CN105828821B/zh active Active
- 2014-12-18 KR KR1020167016182A patent/KR20160093025A/ko not_active Withdrawn
-
2016
- 2016-06-15 IL IL246253A patent/IL246253A0/en unknown
- 2016-06-17 CL CL2016001570A patent/CL2016001570A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252596A0 (en) | History of azabicyclooctane as fxr agonists for use in the treatment of liver and gastrointestinal diseases | |
| JP2016515522A5 (enExample) | ||
| IL256085B (en) | A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment | |
| JP2016518337A5 (enExample) | ||
| HUE066591T2 (hu) | 8-ciano-5-piperidino-kinolinok, mint TLR7/8 antagonisták és alkalmazásuk immunrendellenességek kezelésére | |
| JP2015503422A5 (enExample) | ||
| MA39710A (fr) | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin | |
| WO2014180889A8 (en) | Methods and compositions for the treatment of cancer | |
| JP2014530840A5 (enExample) | ||
| JP2016535100A5 (enExample) | ||
| LT3102575T (lt) | Naujos druskos ir jų farmacinės kompozicijos uždegiminiams sutrikimams gydyti | |
| HUE036084T2 (hu) | Buprenorfin dimer és alkalmazása gasztrointesztinális rendellenességek kezelésénél | |
| EP3229824A4 (en) | Oral octreotide administered in combination with other therapeutic agents | |
| JP2016540026A5 (enExample) | ||
| HUE046924T2 (hu) | Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra | |
| HUE045025T2 (hu) | Heterobiciklusos vegyületek és alkalmazásuk tuberkulózis kezelésére | |
| JP2016540019A5 (enExample) | ||
| LT3157522T (lt) | Muskarininiai antagonistai ir jų deriniai, skirti arklių kvėpavimo takų ligos gydymui | |
| WO2015173701A3 (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
| TWD172918S (zh) | 刀型玩具之部分 | |
| IL280389A (en) | Bile acid receptor modulators conjugated to G.1 protein and methods of using them | |
| EP3162377A4 (en) | Use of -asarone in preparing drugs for preventing and treating alzheimer's disease | |
| IL248428B (en) | 3,1-propanedisulfonic acid or its pharmaceutically acceptable salt for use in the treatment of sarcoidosis | |
| EA201692426A1 (ru) | Комбинации зальтопрофена и миорелаксанта | |
| JP2017516883A5 (enExample) |